 Lisa Pomrenke on Aug 17th, 2018 // No Comments
Viking Therapeutics Inc (NASDAQ:VKTX) â€“ Equities research analysts at Zacks Investment Research boosted their Q3 2018 earnings per share estimates for Viking Therapeutics in a research report issued to clients and investors on Monday, August 13th. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.11). Zacks Investment Research also issued estimates for Viking Therapeutics' Q4 2018 earnings at ($0.10) EPS, FY2018 earnings at ($0.41) EPS and FY2019 earnings at ($0.39) EPS. Get Viking Therapeutics alerts:
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). VKTX has been the subject of several other research reports. ValuEngine raised shares of Viking Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 29th. SunTrust Banks started coverage on shares of Viking Therapeutics in a research report on Friday, July 20th. They issued a "buy" rating and a $14.00 price objective for the company. Maxim Group reissued a "buy" rating and issued a $14.00 price objective (up previously from $8.00) on shares of Viking Therapeutics in a research report on Thursday, May 31st. Laidlaw increased their price objective on shares of Viking Therapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, June 1st. Finally, Raymond James started coverage on shares of Viking Therapeutics in a research report on Thursday, June 28th. They issued an "outperform" rating and a $15.00 price objective for the company. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Viking Therapeutics presently has an average rating of "Buy" and an average target price of $14.33.
Shares of VKTX stock opened at $10.54 on Wednesday. Viking Therapeutics has a one year low of $0.97 and a one year high of $13.43. The company has a market cap of $628.41 million, a P/E ratio of -13.34 and a beta of 2.74.
Several institutional investors have recently added to or reduced their stakes in VKTX. Geode Capital Management LLC increased its position in shares of Viking Therapeutics by 276.2% in the fourth quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company's stock worth $477,000 after acquiring an additional 86,355 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Viking Therapeutics by 124.4% in the fourth quarter. Renaissance Technologies LLC now owns 903,300 shares of the biotechnology company's stock valued at $3,667,000 after purchasing an additional 500,700 shares during the period. Millennium Management LLC purchased a new position in shares of Viking Therapeutics in the fourth quarter valued at $2,854,000. Trexquant Investment LP purchased a new position in shares of Viking Therapeutics in the first quarter valued at $281,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Viking Therapeutics by 210.8% in the first quarter. Victory Capital Management Inc. now owns 605,794 shares of the biotechnology company's stock valued at $2,647,000 after purchasing an additional 410,864 shares during the period. 34.94% of the stock is owned by institutional investors.
In other Viking Therapeutics news, Director Lawson Macartney acquired 47,965 shares of the company's stock in a transaction dated Tuesday, May 29th. The stock was bought at an average price of $5.22 per share, with a total value of $250,377.30. Following the completion of the transaction, the director now directly owns 47,965 shares of the company's stock, valued at $250,377.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, Director J Matthew Singleton acquired 9,500 shares of the company's stock in a transaction dated Thursday, May 31st. The stock was acquired at an average cost of $9.82 per share, with a total value of $93,290.00. Following the transaction, the director now directly owns 9,500 shares of the company's stock, valued at $93,290. The disclosure for this purchase can be found here . 3.90% of the stock is owned by corporate insiders.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures